Ablynx signs Sanofi deal potentially worth up to $2.8 bln

(Reuters) - French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).